PDCD1 and vitiligo: Given that PD-1 is expressed by both peripheral regulatory CD4+ and cytotoxic CD8+ T cells in vitiligo patients, we reasoned that agonistic PD-1/PD-L1 therapy might suppress melanocyte-reactive T cells, but concomitantly suppress regulatory T cells.